278 related articles for article (PubMed ID: 37494097)
1. Co-Constructing a Community-Based Telemedicine Program for People With Opioid Use Disorder During the COVID-19 Pandemic: Lessons Learned and Implications for Future Service Delivery.
Høj SB; de Montigny C; Chougar S; Léandre R; Beauchemin-Nadeau MÈ; Boyer-Legault G; Goyette A; Lamont SK; Bruneau J
JMIR Public Health Surveill; 2023 Jul; 9():e39236. PubMed ID: 37494097
[TBL] [Abstract][Full Text] [Related]
2. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
Crowley D; Delargy I
Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
[TBL] [Abstract][Full Text] [Related]
3. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
Krawczyk N; Fawole A; Yang J; Tofighi B
Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic.
Castillo M; Conte B; Hinkes S; Mathew M; Na CJ; Norindr A; Serota DP; Forrest DW; Deshpande AR; Bartholomew TS; Tookes HE
Harm Reduct J; 2020 Nov; 17(1):88. PubMed ID: 33203460
[TBL] [Abstract][Full Text] [Related]
5. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
[TBL] [Abstract][Full Text] [Related]
6. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
8. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
[TBL] [Abstract][Full Text] [Related]
9. Scaling and Sustaining Facilitated Telemedicine to Expand Treatment Access Among Underserved Populations: A Qualitative Study.
Ventuneac A; Dickerson SS; Dharia A; George SJ; Talal AH
Telemed J E Health; 2023 Dec; 29(12):1862-1869. PubMed ID: 37252770
[No Abstract] [Full Text] [Related]
10. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
11. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
[TBL] [Abstract][Full Text] [Related]
12. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19.
Levander XA; Wheelock H; Pope J; Lee A; Hartmann K; Abuelkhair S; Gregg JL; Buchheit BM
J Addict Med; 2022 Jan-Feb 01; 16(1):e56-e58. PubMed ID: 34374502
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
14. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
[TBL] [Abstract][Full Text] [Related]
15. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.
Harris R; Rosecrans A; Zoltick M; Willman C; Saxton R; Cotterell M; Bell J; Blackwell I; Page KR
Drug Alcohol Depend; 2022 Jan; 230():109187. PubMed ID: 34890927
[TBL] [Abstract][Full Text] [Related]
16. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
17. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
18. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
[TBL] [Abstract][Full Text] [Related]
19. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
[TBL] [Abstract][Full Text] [Related]
20. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
